All Stories

  1. Validation of an Automated CT Image Analysis in the Prevention of Urinary Stones with Hydration Trial
  2. Factors associated with erectile dysfunction in men with lower urinary tract symptoms (LUTS): a Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) study
  3. Unplanned Health Care Utilization after Ureteroscopy with Ureteral Stenting: Results from the Study to Enhance Understanding of Stent-Associated Symptoms Cohort
  4. Pain After Ureteroscopy Varies by Sex and Stone Location: Findings from STENTS Study
  5. Development of Prediction Models for Severe Pain and Urinary Symptoms After Ureteroscopy With Ureteral Stent Placement: Results From the STENTS Study and Initial Validation of Pain Interference
  6. Expanded Physiological Testing of the Lower Urinary Tract in Asymptomatic Women and Those With Urgency Urinary Incontinence: Findings From the LURN‐Organ Study
  7. Widespread pain phenotypes impact treatment efficacy results in randomized clinical trials for interstitial cystitis/bladder pain syndrome: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain network study
  8. Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN): An introduction to the Urinary Urgency Phenotyping Protocol LURN II
  9. Using structured problem solving to promote fluid consumption in the prevention of urinary stones with hydration (PUSH) trial
  10. Contribution of Hypersensitivity to Postureteroscopy Ureteral Stent Pain: Findings From Study to Enhance Understanding of Stent-associated Symptoms
  11. Epidemiology of Infantile Ureteropelvic Junction Obstruction in the US
  12. Naturalistic Bladder Filling Reveals Subtypes in Overactive Bladder Syndrome That Differentially Engages Urinary Urgency-Related Brain Circuits: Results From the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  13. Reply By Authors
  14. Patients’ Experiences With the Removal of a Ureteral Stent: Insights From In-depth Interviews With Participants in the USDRN STENTS Qualitative Cohort Study
  15. Relationships Between Urinary and Nonurinary Symptoms in Treatment-Seeking Women in LURN
  16. Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study
  17. The Patient Voice: Stent Experiences After Ureteroscopy—Insights from In-Depth Interviews with Participants in the USDRN STENTS Nested Qualitative Cohort Study
  18. Risk Factors for Increased Stent-associated Symptoms Following Ureteroscopy for Urinary Stones: Results From STENTS
  19. Widespread Pain Phenotypes Impact Treatment Efficacy Results in Randomized Clinical Trials for Interstitial Cystitis/ Bladder Pain Syndrome: A MAPP Network Study
  20. Phenotyping of Urinary Urgency Patients Without Urgency Incontinence, and Their Comparison to Urgency Incontinence Patients: Findings From the LURN Study
  21. Total fluid intake, caffeine, and other bladder irritant avoidance among adults having urinary urgency with and without urgency incontinence: The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  22. Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study
  23. Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  24. Evolution of healthcare costs for lower urinary tract symptoms associated with benign prostatic hyperplasia
  25. Impact of Sleep Disturbance, Physical Function, Depression and Anxiety on Male Lower Urinary Tract Symptoms: Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  26. Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTS
  27. Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study
  28. Reply by Authors
  29. Resolution of Hydronephrosis and Pain to Predict Stone Passage for Patients With Acute Renal Colic
  30. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia
  31. Impact of COVID-19 on Prevention of Urinary Stones with Hydration (PUSH) Study: Challenges and Opportunities for Future Trials
  32. Analgesic and Opioid Use for Patients Discharged from the Emergency Department with Ureteral Stones
  33. Prevalence of Urinary Incontinence among a Nationally Representative Sample of Women, 2005–2016: Findings from the Urologic Diseases in America Project
  34. Prevention of Urinary Stones With Hydration (PUSH): Design and Rationale of a Clinical Trial
  35. Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design
  36. National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project
  37. Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms
  38. Patient demographic and psychosocial characteristics associated with 30‐day recall of self‐reported lower urinary tract symptoms
  39. Prevalence, subtypes, and correlates of nocturia in the symptoms of Lower Urinary Tract Dysfunction Research Network cohort
  40. Accuracy of Patient Reported Stone Passage for Patients With Acute Renal Colic Treated in the Emergency Department
  41. National Trends in the Surgical Management of Urinary Incontinence among Insured Women, 2004 to 2013: The Urologic Diseases in America Project
  42. A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10
  43. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project
  44. Symptom Based Clustering of Men in the LURN Observational Cohort Study
  45. Longitudinal changes in symptom‐based female and male LUTS clusters
  46. Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses
  47. Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?
  48. U.S. Adolescent and Adult Women’s Experiences Accessing and Using Toilets in Schools, Workplaces, and Public Spaces: A Multi-Site Focus Group Study to Inform Future Research in Bladder Health
  49. Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms
  50. Acyloxyacyl hydrolase modulates depressive-like behaviors through aryl hydrocarbon receptor
  51. The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations
  52. Are three‐day voiding diaries feasible and reliable? Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) cohort
  53. A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study
  54. Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project
  55. Strengthening Research in Benign Urology: Dispelling Myths that Impede Success
  56. A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index‐29 (LURN SI‐29) questionnaire
  57. The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms
  58. Optimization of DNA extraction from human urinary samples for mycobiome community profiling
  59. A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network
  60. Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms
  61. Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study
  62. Symptom Based Clustering of Women in the LURN Observational Cohort Study
  63. The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations
  64. Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence
  65. Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones
  66. Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study
  67. Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop
  68. NIH research opportunities for the prevention and treatment for chronic conditions
  69. Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence
  70. MP27-09 RELATIONSHIPS BETWEEN METABOLIC FACTORS, URINARY INCONTINENCE AND OVERACTIVE BLADDER SYMPTOMS AMONG MEN AND WOMEN IN THE LURN OBSERVATIONAL COHORT STUDY
  71. Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study
  72. Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study
  73. Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review
  74. Re: Top cited articles in urology from Turkey
  75. PNFLBA-04 RANDOMIZED CLINICAL TRIAL OF TREATMENT WITH TAMSULOSIN BEGUN IN THE EMERGENCY DEPARTMENT TO PROMOTE PASSAGE OF URINARY STONES
  76. Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department
  77. Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome
  78. Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms
  79. Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia
  80. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement
  81. Symptoms of Lower Urinary Tract Dysfunction Research Network
  82. Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health
  83. Do we need new patient reported measures to evaluate lower urinary tract dysfunction?
  84. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
  85. Quality of Acute Care for Patients With Urinary Stones in the United States
  86. Urinary Stone Disease: Progress, Status, and Needs
  87. Relationship between Chronic Nonurological Associated Somatic Syndromes and Symptom Severity in Urological Chronic Pelvic Pain Syndromes: Baseline Evaluation of the MAPP Study
  88. PD39-01 SEXUAL FUNCTION ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: MTOPS COHORT OF CROSS-SECTIONAL AND LONGITUDINAL DATA
  89. Emergency Department Revisits for Patients with Kidney Stones in California
  90. Re: Cross-Sectional and Longitudinal Associations of Sexual Function with Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  91. The International Prostate Forum introduction and history
  92. Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors
  93. Cross-Sectional and Longitudinal Associations of Sexual Function with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  94. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes
  95. The MAPP research network: design, patient characterization and operations
  96. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer
  97. Comparative Effectiveness of Shock Wave Lithotripsy and Ureteroscopy for Treating Patients With Kidney Stones
  98. Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy
  99. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer
  100. Genito-Urological Cancers in Elderly Patients
  101. Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur ...
  102. Can We Change Patient Behaviors to Improve Urological Health?
  103. Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia
  104. Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States
  105. Somatostatin receptor expression in prostate carcinoma: the urological pathologist’s role in the era of personalised medicine
  106. Active surveillance for small renal tumors: Have clinical concerns been addressed so far?
  107. Positive Surgical Margins After Nephron-Sparing Surgery
  108. Lymphocytic vasculitis of the prostate transition zone
  109. Unclassified renal cell carcinoma: a report of 56 cases
  110. Basic Research in Kidney Cancer
  111. Renal Cell Carcinoma: A Changing Paradigm With a Need for Consensus
  112. ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
  113. International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma
  114. Contemporary Management of Small Renal Masses
  115. Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and Hig...
  116. 70 INVITED New Approaches in Surgical Management of Renal Cancer
  117. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
  118. Management of advanced prostate cancer – new drugs
  119. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility
  120. 716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB
  121. Toxicities of Targeted Therapy and Their Management in Kidney Cancer
  122. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 tria...
  123. Reply to Kiril Trpkov, Asli Yilmaz’ Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patien...
  124. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Tria...
  125. Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited
  126. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use
  127. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma
  128. Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
  129. Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors
  130. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient’s Pathology and Clinical Reports
  131. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-ri...
  132. Editorial Comment on: Predicting Occult Multifocality of Renal Cell Carcinoma
  133. Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications. Eur Uro...
  134. Reply to Tomasso Cai, Lorenzo Giuseppe Luciani and Gianni Malossini’s Letter to the Editor re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comp...
  135. Ablative therapies in the treatment of small renal tumors: How far from standard of care?
  136. Reply from Authors re: Marko Babjuk. New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma. Eur Urol 2010;57:774–6
  137. The Changing Face of Renal-Cell Carcinoma
  138. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Ri...
  139. 189 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993
  140. 1474 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993
  141. Reply to José I. Lopéz's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and ...
  142. A Critical Analysis of the Actual Role of Minimally Invasive Surgery and Active Surveillance for Kidney Cancer
  143. The Motion: Cryotherapy is an Efficient Alternative for Kidney Cancer
  144. Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better
  145. What is new in kidney cancer?
  146. Kidney cancer in the elderly
  147. Genetic profiles in renal tumors
  148. Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance
  149. Secondary neoplasms of the urinary system and male genital organs
  150. Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer
  151. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?
  152. Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?
  153. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance
  154. Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
  155. Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique
  156. 2009 update on the classification of renal epithelial tumors in adults
  157. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
  158. Urologic oncology in southern Europe: Perceived problems and current plans
  159. 914 PREDICTION OF PROSTATIC INVOLVEMENT BY UROTHELIAL CARCINOMA AND OF INCIDENTAL PROSTATE CANCER IN RADICAL CYSTOPROSTATECTOMIES FOR BLADDER CANCER
  160. Editorial Comment on: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
  161. Multigene Methylation Analysis of Conventional Renal Cell Carcinoma
  162. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications
  163. Editorial Comment on: Results of Endoluminal Occlusion of the Inferior Vena Cava During Radical Nephrectomy and Thrombectomy
  164. Rare and unusual histological variants of prostatic carcinoma: clinical significance
  165. Will We Be Able to “Cure” Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?
  166. Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance
  167. Splitting and Lumping Adult Renal Epithelial Tumors Can Help the Urologists in the Prognostic Risk Stratification and in the Treatment Decision-Making
  168. PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911
  169. PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911
  170. Open Partial Nephrectomy in the Management of Small Renal Masses
  171. Chairmen's Summary
  172. Renal Cell Carcinoma: Overview
  173. A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  174. Reply to Apostolos P. Labanaris et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  175. There has to be a Way
  176. Re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  177. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion
  178. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  179. Rebuttal from Authors re: Carlo Terrone, Alessandro Volpe. The Role of Pathology for Clinical Decision-Making in Renal Cell Carcinoma is Increasing. Eur Urol 2007;51:1166–8
  180. What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?
  181. Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
  182. Re: Nephroureterectomy for Treating Upper Urinary Tract Transitional Cell Carcinoma. Time to Change the Treatment Paradigm?
  183. 1728: A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  184. The motion: Open partial nephrectomy is the standard of care for small resectable solid renal masses
  185. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  186. Editorial: Superficial Bladder Cancer
  187. Reply to Dr Özdemir’s Letter to the Editor re: Burcin Tuna, Kutsal Yorukoglu, Mehtat Unlu, M. Ugur Mungan and Ziya Kirkali, Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. Eur Urol. 2006;50:530–34
  188. Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas
  189. Puigvert: A Man with a Vision—Nephron-Sparing Surgery 30 Years Ago in Europe
  190. Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma
  191. Phase III intermittent MAB vs continuous MAB
  192. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate
  193. 2004 WHO Classification of the Renal Tumors of the Adults
  194. Expression of Cathepsin D in Bladder Carcinoma: Correlation with Pathological Features and Serum Cystatin C Levels
  195. Are We Really Making an Advance in the Treatment of Metastatic Renal Cell Carcinoma?
  196. Beyond Skeletal-Related Events
  197. Superficial Urothelial Cancer in the Prostatic Urethra
  198. Superficial Urothelial Cancer in the Prostatic Urethra
  199. Editorial: Superficial Bladder Cancer
  200. The Future of Oncological Urology in Europe: Are we Prepared?
  201. Bladder cancer: Epidemiology, staging and grading, and diagnosis
  202. Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder
  203. Echo Contrast-Enhanced Power Doppler Ultrasonography for Assessment of Angiogenesis in Renal Cell Carcinoma
  204. Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?
  205. 1,25 Dihydroxyvitamin D Receptor Expression in Superficial Transitional Cell Carcinoma of the Bladder: A Possible Prognostic Factor?
  206. Significance of COX-2 expression in human renal cell carcinoma
  207. Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report
  208. Significance of heat shock protein-27 expression in patients with renal cell carcinoma
  209. Handling and Pathology Reporting of Adrenal Gland Specimens
  210. Conservative Management of Mucosal Prostatic Urethral Involvement in Patients with Superficial Transitional Cell Carcinoma of the Bladder
  211. Handling and Pathology Reporting of Renal Tumor Specimens
  212. Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery
  213. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder
  214. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma
  215. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder
  216. Clinical Aspects of Renal Cell Carcinoma
  217. Renal cell carcinoma: new prognostic factors?
  218. Bone Mineral Density and Biochemical Markers of Bone in Patients With Idiopathic Hypercalciuria
  219. RE: Etiology of Spontaneous Perirenal Hemorrhage: A Meta-Analysis
  220. Transitional cell carcinoma of the ureter and renal pelvis
  221. Primary renal lymphoma of mucosa-associated lymphoid tissue
  222. Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer
  223. Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer
  224. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  225. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  226. Prognostic significance of nuclear morphometry in renal cell carcinoma
  227. Prognostic Significance of Estrogen Receptor Expression in Superficial Transitional Cell Carcinoma of the Urinary Bladder
  228. Management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder
  229. Phase III study of intermittent MAB versus continuous MAB international cooperative study
  230. A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell Carcinoma--A Preliminary Attempt at Surgical Quality Control
  231. Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor
  232. Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma
  233. Recent advances in kidney cancer and metastatic disease
  234. Vertebral Fracture Associated with Shockwave Lithotripsy in a Patient with Granulomatous Spondylitis
  235. INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-...
  236. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?
  237. METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: SUBCELLULAR LOCALIZATION AND PROGNOSTIC SIGNIFICANCE
  238. Quality control of radical prostatectomy
  239. Premalignant Lesions in the Kidney
  240. Expression of PS2 Protein and Its Relation with the Ki–67 Proliferative Indices and Tumor Recurrence in Superficial Bladder Carcinomas
  241. Renal Cancer
  242. Significance of Tissue Laminin P<sub>1</sub> Elastase and Fibronectin Levels in Transitional Cell Carcinoma of the Bladder
  243. Renal Cancer
  244. Precancerous Lesions in the Kidney
  245. Ganglion cells in the human prostate
  246. Prognostic Significance of Microvascular Invasion in Localized Renal Cell Carcinoma
  247. RE: RECURRENT BILATERAL AMIODARONE INDUCED EPIDIDYMITIS
  248. Prognostic significance of angiogenesis and immunoreactivity of cathepsin d and type IV collagen in high-grade stage T1 primary bladder cancer
  249. PHARMACOLOGICAL ANALYSIS OF 5-HYDROXYTRYPTAMINE EFFECTS ON HUMAN ISOLATED URETER
  250. Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma
  251. RE
  252. RE: URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER
  253. Comparison of Microvascularization in Diagnostic Needle Biopsies and Radical Prostatectomies in Prostate Carcinoma
  254. Radical Nephrectomy with and without Lymph Node Dissection: Preliminary Results of the EORTC Randomized Phase III Protocol 30881
  255. Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume
  256. Renal Effects of Carbon Dioxide Insufflation in Rabbit Pneumoretroperitoneum Model
  257. Volume-weighted mean nuclear volume in renal cell carcinoma
  258. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  259. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  260. Renal Cell Carcinoma with Gallbladder Metastasis
  261. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters
  262. Is Magnetic Resonance Imaging Necessary in the Staging of Prostate Cancer?
  263. Locally Recurrent Paratesticular Rhabdomyosarcoma Treated with Surgery and Radiotherapy
  264. Testicular Microlithiasis Associated with Teratocarcinoma and Intratubular Germ Cell Neoplasia: A Case Report
  265. Contractility Changes of the Deep Dorsal Penile Vein Due to Serotonin
  266. Ignificance of serum lam1nin P1 values in patients with transitional cell carcinoma of the bladder
  267. Effect of Extracorporeal Shockwave Lithotripsy on Plasma and Urine Endothelin Concentrations
  268. Bellini duct (collecting duct) carcinoma of the kidney
  269. Primary Kaposi's sarcoma of the glans penis
  270. Effectiveness of Extracorporeal Shockwave Lithotripsy in the Management of Stone-Bearing Horseshoe Kidneys
  271. 99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between99mTc-MIBI uptake and P-alvcoprotein expression in tumour tissue
  272. Cisplatin and Etoposide Chemotherapy in the Treatment of Adult Wilms’ Tumor
  273. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  274. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  275. Prostatic carcinoma presenting with painless parotid mass
  276. Influence of Serotonin on the Human Ureter: An in vitro Pharmacological Study
  277. Effect of Ejaculation on Prostate-Specific Antigen Levels in Normal Men
  278. Ferritin: A Tumor Marker Expressed by Renal Cell Carcinoma
  279. The effect of extracorporeal shock wave lithotripsy on pancreatic enzymes
  280. Magnetic resonance imaging in the staging of renal cell carcinoma
  281. Does Respiratory Gating Improve Extracorporeal Shockwave Lithotripsy Results?
  282. Beh�et's disease: Urogynecological manifestations in women
  283. Open stone surgery: Is it still a preferable procedure in the management of staghorn calculi?
  284. The effect of extracorporeal electromagnetic shock waves on renal proximal tubular function
  285. Primary signet-ring cell carcinoma of the bladder
  286. Are Obstructing Ureteral Stones More Difficult to Treat with Extracorporeal Electromagnetic Shock Wave Lithotripsy?*
  287. Extracorporeal Electromagnetic Shock Wave Lithotripsy of Ureteric Stones in Situ
  288. Carcinoma of the prostate and HLA antigens
  289. Carcinoma of the bladder in patients less than 40 years old
  290. Urological Aspects of Behcet's Disease
  291. Cysts of the Prostate, Seminal Vesicles and Diverticulum of the Ejaculatory Ducts
  292. Silent Testicular Metastasis from Carcinoma of the Prostate
  293. Tunica Vaginalis: an Aid in Hypospadias Surgery
  294. Androgen receptors in transitional cell carcinoma
  295. HLA Antigens and Transitional Cell Carcinoma of the Bladder
  296. Androgen Receptors - A Method to Measure Functional Behaviour in Human Prostatic Cancer
  297. Epidemiological Case-Control Study on the Etiology of Bladder Cancer in Turkey
  298. Urothelial Tumours of the Upper Urinary Tract
  299. Bladder agenesis
  300. Ureterorenoscopy: A new approach in the diagnosis and treatment of upper urinary tract disorders
  301. Amiodarone-Induced Sterile Epididymitis
  302. Blood Groups and Transitional Cell Carcinoma of the Upper Urinary Tract
  303. Spontaneous Kidney Rupture in Polyarteritis nodosa Report of Four Cases
  304. The use of oxybutynin in urological practice
  305. Ureteric perforation after ureteroscopy
  306. Androgen receptors in TCC
  307. Unusual Metastases of Renal Cell Carcinoma
  308. The role of delay in stage III testicular tumours
  309. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate
  310. The Role of Delay in Stage-Ill Testicular Tumors
  311. Haemoglobin F Levels in Patients with Testicular Tumours
  312. Experience with Treatment of Nonseminomatous Germ Cell Tumors of Testis in Turkey
  313. Advanced Tumors: Tumor Thrombus